FAPI-PET/CT Shows Superiority in Detecting Head and Neck Cancer

FAPI-PET/CT Shows Superiority in Detecting Head and Neck Cancer

A recent study published in the Journal of Nuclear Medicine has found that fibroblast activation protein inhibitor (FAPI)-PET/CT outperforms FDG-PET/CT in detecting primary tumors in patients with head and neck cancer. The research suggests that FAPI-PET/CT could offer a sensitive and reliable imaging technique for these patients.

Head and neck cancer of unknown primary presents a challenge for diagnosis, as patients often have enlarged lymph nodes but the origin of the cancer is unknown. Current techniques such as CT, MRI, nasopharyngoscopy, and laryngoscopy have low detection rates for primary tumors. F-18 FDG PET/CT, which visualizes glucose metabolism in tumor cells, has shown some improvement in detection rates, but it can also lead to false-positive findings due to uptake in inflamed tissue.

In contrast, FAPI radiotracers like gallium-68 (Ga-68) FAPI have shown promise in detecting disease. These tracers specifically bind to fibroblast cells in the supportive tissue of tumors. The study tested the effectiveness of FAPI-PET/CT in head and neck cancer patients with tumors of unknown origin in a prospective clinical trial.

The researchers enrolled 91 patients with negative or equivocal findings of primary tumors. They performed F-18 FDG and Ga-68 FAPI-PET/CT within one week and recorded the presence of primary tumors on the imaging sets. The analysis showed that Ga-68 FAPI-PET/CT detected more primary lesions than F-18 FDG PET/CT and demonstrated better sensitivity, positive predictive value, and accuracy in locating primary tumors.

Furthermore, Ga-68 FAPI-PET/CT led to improved treatment changes in a significant percentage of patients. The study adds to the promising results of FAPI-PET/CT imaging in various other head and neck cancers, such as nasopharyngeal carcinoma, oropharyngeal cancer, and salivary ductal carcinoma.

Given the poor five-year overall survival rate for head and neck cancer patients with unknown primary tumors, further studies are warranted. The researchers emphasized the need for a multicenter trial to verify their findings. FAPI-PET/CT holds the potential to significantly improve the diagnosis and treatment of head and neck cancer, offering hope for better outcomes for patients.

Frequently Asked Questions (FAQs)

1. What did the recent study in the Journal of Nuclear Medicine find?
The study found that fibroblast activation protein inhibitor (FAPI)-PET/CT performs better than FDG-PET/CT in detecting primary tumors in patients with head and neck cancer. FAPI-PET/CT could be a sensitive and reliable imaging technique for these patients.

2. Why is head and neck cancer of unknown primary challenging to diagnose?
Head and neck cancer of unknown primary is difficult to diagnose because patients often have enlarged lymph nodes but the origin of the cancer is unknown. Current techniques such as CT, MRI, nasopharyngoscopy, and laryngoscopy have low detection rates for primary tumors.

3. What is F-18 FDG PET/CT?
F-18 FDG PET/CT is a technique that visualizes glucose metabolism in tumor cells. It has shown some improvement in detection rates for primary tumors in head and neck cancer patients, but it can also lead to false-positive findings.

4. How do FAPI radiotracers work?
FAPI radiotracers, such as gallium-68 (Ga-68) FAPI, bind specifically to fibroblast cells in the supportive tissue of tumors. They have shown promise in detecting disease.

5. What were the findings of the study regarding FAPI-PET/CT?
The study enrolled 91 patients with negative or equivocal findings of primary tumors. Ga-68 FAPI-PET/CT, when compared to F-18 FDG PET/CT, detected more primary lesions and demonstrated better sensitivity, positive predictive value, and accuracy in locating primary tumors.

6. Has FAPI-PET/CT shown positive results in other head and neck cancers?
Yes, FAPI-PET/CT imaging has shown promising results in various other head and neck cancers, such as nasopharyngeal carcinoma, oropharyngeal cancer, and salivary ductal carcinoma.

7. What is the significance of further studies?
Given the poor five-year overall survival rate for head and neck cancer patients with unknown primary tumors, further studies are needed. The researchers emphasized the need for a multicenter trial to verify their findings and explore the potential of FAPI-PET/CT in improving the diagnosis and treatment of head and neck cancer.

Related Links:
Journal of Nuclear Medicine

All Rights Reserved 2021
| .
Privacy policy
Contact